KEYTRUDA

• KEYTRUDA has a marketing authorisation in combination with carboplatin and either paclitaxel or nab-paclitaxel as a first-line treatment for adult patients with metastatic squamous non-small cell lung carcinoma (NSCLC).
• The superiority of KEYTRUDA in combination with carboplatin + paclitaxel/nab-paclitaxel compared to carboplatin + paclitaxel/nab-paclitaxel was demonstrated in terms of progression-free survival (increase of + 1.6 months) and overall survival (increase of + 4.6 months) in an interim analysis with a median follow-up of 8.3 months in the pembrolizumab group and 7.4 months in the placebo group.
• The transposability of the data to the French population is limited given that 40% of patients received the nab-paclitaxel + carboplatin combination, not cited in French national recommendations.
• No robust quality of life data are available.

-